Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Hoffmann-La Roche
Baylor College of Medicine
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Haihe Biopharma Co., Ltd.
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Istituto Oncologico Veneto IRCCS
Turning Point Therapeutics, Inc.
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Centre Leon Berard
Washington University School of Medicine
Essen Biotech
National Cancer Centre, Singapore
University Health Network, Toronto
IGM Biosciences, Inc.
Lantern Pharma Inc.
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Ipsen
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cyteir Therapeutics, Inc.
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Washington University School of Medicine
Hutchmed
Cedars-Sinai Medical Center
Rigshospitalet, Denmark
University of Virginia
Presage Biosciences
Catalysis SL
UNICANCER
Corvus Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, LLC
Karolinska University Hospital